Korro Bio (KRRO) Projected to Post Earnings on Wednesday

Korro Bio (NASDAQ:KRRO) is expected to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($1.2619) per share and revenue of $0.19 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Thursday, August 6th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.27. On average, analysts expect Korro Bio to post ($4.95) EPS for the current fiscal year and ($4.46) EPS for the next fiscal year.

Korro Bio Trading Up 0.1%

Shares of NASDAQ:KRRO opened at $15.86 on Wednesday. The business’s 50-day simple moving average is $11.51 and its 200 day simple moving average is $11.96. Korro Bio has a one year low of $5.20 and a one year high of $38.42.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Korro Bio in a research report on Tuesday, October 6th. Wall Street Zen raised shares of Korro Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Jefferies Financial Group set a $15.00 target price on shares of Korro Bio in a research note on Tuesday, October 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a report on Friday, October 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Korro Bio presently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Insider Buying and Selling

In other Korro Bio news, major shareholder Lynx1 Capital Management Lp acquired 52,175 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were bought at an average cost of $10.72 per share, for a total transaction of $559,316.00. Following the acquisition, the insider directly owned 1,597,155 shares of the company’s stock, valued at $17,121,501.60. This trade represents a 3.38% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Formela sold 28,468 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $14.00, for a total value of $398,552.00. Following the completion of the transaction, the director directly owned 141,053 shares in the company, valued at approximately $1,974,742. The trade was a 16.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have acquired 86,493 shares of company stock worth $963,734 and have sold 38,269 shares worth $532,064. Insiders own 4.80% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company’s approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient’s DNA.

Korro Bio’s technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.